AI summary · may contain errors
Switching to camizestrant plus CDK4/6 inhibitor at ESR1 mutation emergence improved median progression-free survival to 16·8 months versus 9·2 months with aromatase inhibitor plus CDK4/6 inhibitor in SERENA-6.
- 21 cites
